Authors : Shweta Arora; Dr. Balakrishna Grandhi; Dr. Shital Vakhariya

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/nh9ptkxx

DOI : https://doi.org/10.38124/ijisrt/24may2403

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Despite the promising introduction of Glucagon-like Peptide-1 (GLP-1) analogs in the Indian market for managing diabetes and obesity, their uptake remains limited due to several factors: high costs, lack of outpatient insurance coverage, side effects, limited long-term data on cardiovascular and renal safety, and healthcare professionals' reluctance to prescribe them. This study aims to explore these barriers and propose innovative strategies to enhance the adoption of GLP-1 analogs in India. By applying Rogers' Diffusion of Innovations theory, the research will analyze the adoption process and develop targeted strategies to overcome identified challenges, ultimately benefiting a significant segment of the population struggling with diabetes and obesity.

References :

1. Lancet, T. (2023). Diabetes: a defining disease of the 21st century. Lancet (London, England), 401(10394), 2087.
2. Pradeepa, R., & Mohan, V. (2021). Epidemiology of type 2 diabetes in India. Indian journal of ophthalmology, 69(11), 2932-2938.
3. Deepa, M., Anjana, R. M., & Mohan, V. (2017). Role of lifestyle factors in the epidemic of diabetes: lessons learnt from India. European journal of clinical nutrition, 71(7), 825-831.
4. Wong, L. P., Lee, H. Y., Alias, H., Zimet, G., Liu, T., Lin, Y., & Hu, Z. (2024). Cost- based COVID-19 vaccination and willingness to pay: A post-pandemic review. Human Vaccines & Immunotherapeutics, 20(1), 2313860.
5. Dearing, J. W., & Cox, J. G. (2018). Diffusion of innovations theory, principles, and practice. Health affairs, 37(2), 183-190.
6. Wang, J. Y., Wang, Q. W., & Yang, X. Y. (2023). GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol (Lausanne). 2023; 14: 1085799
7. Misra A, Khurana L. Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes (Lond). 2011;35(2):167-187.
8. Patel D, Kumar A, Patel P, Gyawali B, Mehta D. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes care: a comprehensive review of their safety and efficacy. Diabetes Metab Syndr Obes. 2020;13:893-905.
9. Prasad K, Dhar R. Emerging trends in cardiovascular diseases in India: lessons from the Covid-19 pandemic. Am J Cardiovasc Drugs. 2021;21(5):459-466.
10. Ghosal S, Sinha B, Majumder M, et al. Drug pricing policy in India: current trends and future implications. J Pharm Policy Pract. 2016;9:12.
11. Mohan V, Shah S, Saboo B. Current glycemic status and diabetes related complications among type 2 diabetes patients in India: data from the A1chieve study. J Assoc Physicians India. 2013;61(1 Suppl):12-15.
12. Chawla R, Madhu S, Makkar B, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020;24(1):1-122.
13. Nauck, M. A., et al. "GLP-1 receptor agonists in the treatment of type 2 diabetes– state-of-the-art. Mol Metab 2021; 46: 101102." (2020).
14. Lancet, The. "Diabetes: a defining disease of the 21st century." Lancet (London, England) 401.10394 (2023): 2087.
15. Karunarathna, Indunil, and P. Jayathilaka. "Comprehensive Management of Type 2 Diabetes Mellitus: From Prevention to Novel Therapeutic Approaches." Uva Clinical Lab. Retrieved from Comprehensive Management of Type 2 (2024).
16. Polonsky, William, et al. "Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: a qualitative study." Diabetes Spectrum 34.2 (2021): 175-183.
17. Karagiannis, Thomas, Eleni Bekiari, and Apostolos Tsapas. "Socioeconomic aspects of incretin-based therapy." Diabetologia 66.10 (2023): 1859-1868.
18. Chen, Yongru, et al. "Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes." Frontiers in Pharmacology 15 (2024): 1370594.
19. Ali, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Shivashankar, R., ... & CARRS Trial Group*. (2016). Effectiveness of a multicomponent quality improvement strategy to improve achievement of diabetes care goals: a randomized, controlled trial. Annals of internal medicine, 165(6), 399-408.
20. LaMorte, W. W. (2022). Diffusion of Innovation Theory. Boston University School of Public Health.